The stock of ReNeuron Group Plc (LON:RENE) hit a new 52-week low and has GBX 2.14 target or 12.00% below today’s GBX 2.43 share price. The 8 months bearish chart indicates high risk for the GBX 80.42M company. The 1-year low was reported on Nov, 4 by Barchart.com. If the GBX 2.14 price target is reached, the company will be worth GBX 9.65M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock decreased 3.00% or GBX 0.07 on November 4, hitting GBX 2.43. About 707,466 shares traded hands. ReNeuron Group Plc (LON:RENE) has declined 16.67% since April 6, 2016 and is downtrending. It has underperformed by 17.76% the S&P500.
More recent ReNeuron Group Plc (LON:RENE) news were published by: Uk.Finance.Yahoo.com which released: “ReNeuron Group plc (RENE.L)” on March 29, 2014. Also Fool.Co.Uk published the news titled: “Is ReNeuron Group Plc The Perfect Partner For BTG plc And Shire PLC In Your …” on June 22, 2015. Fool.Co.Uk‘s news article titled: “Should You Invest In Vodafone Group plc, ReNeuron Group Plc Or Zotefoams plc?” with publication date: July 10, 2015 was also an interesting one.
ReNeuron Group plc is a clinical-stage company. The company has a market cap of 80.42 million GBP. The Company, through its subsidiaries, is engaged in researching and developing cell therapies. It currently has negative earnings. The Company’s products are allogeneic.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.